Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 3/20 | 0.59 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.59 |
| ▸ | IDO1 | P14902 | 1/20 | 0.57 |
| ▸ | DYRK1A | Q13627 | 5/20 | 0.54 |
| ▸ | JAK1 | P23458 | 1/20 | 0.50 |
| ▸ | TYK2 | P29597 | 1/20 | 0.50 |
| ▸ | JAK3 | P52333 | 1/20 | 0.50 |
| ▸ | GSK3B | P49841 | 1/20 | 0.49 |
| ▸ | AXL | P30530 | 1/20 | 0.41 |
| ▸ | ABL1 | P00519 | 2/20 | 0.41 |
| ▸ | BCR | P11274 | 2/20 | 0.41 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.40 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.40 |
| ▸ | METAP2 | P50579 | 1/20 | 0.40 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.39 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.39 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.38 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.38 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.38 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17039120 | 0.87 | JAK2 (0.64) | JAK2PDPK1IDO1DYRK1AJAK1 | |
| SCHEMBL261067 | 0.85 | IDO1 (0.62) | JAK2PDPK1IDO1DYRK1AGSK3B | |
| SCHEMBL30075258 | 0.85 | IDO1 (0.62) | JAK2PDPK1IDO1DYRK1AGSK3B | |
| SCHEMBL30301502 | 0.83 | DYRK1A (0.61) | JAK2PDPK1IDO1DYRK1AGSK3B | |
| SCHEMBL15077318 | 0.83 | DYRK1A (0.61) | JAK2PDPK1IDO1DYRK1AGSK3B | |
| SCHEMBL28258656 | 0.83 | CHEK1 (0.53) | JAK2JAK1TYK2JAK3ITGB3 | |
| SCHEMBL8877902 | 0.81 | JAK1 (0.65) | JAK2PDPK1IDO1JAK1TYK2 | |
| SCHEMBL13386744 | 0.80 | JAK2 (0.50) | JAK2DYRK1AJAK1TYK2JAK3 | |
| SCHEMBL15541582 | 0.80 | JAK2 (0.53) | JAK2JAK1TYK2JAK3ABL1 | |
| SCHEMBL16252829 | 0.80 | MAP2K4 (0.52) | JAK2JAK1TYK2JAK3ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12485109-B2 | Pyrrolo 12.3-dipyrimidine compounds and analogues thereof | BIOCRYST PHARMACEUTICALS, INC. (US) | 2025-12-02 | — | — | US | disclosed |
| EP-3925956-B1 | 1H-INDAZOLE-3-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS FACTOR D INHIBITORS FOR TREATING DISEASES CHARACTERIZED BY ABERRANT COMPLEMENT SYSTEM ACTIVITY, SUCH AS E.G. IMMUNOLOGICAL DISORDERS | BIOCRYST PHARM INC (US) | 2024-04-10 | — | — | EP | disclosed |
| US-20230218578-A1 | BENZOPYRAZOLE COMPOUNDS AND ANALOGUES THEREOF | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2023-07-13 | — | — | US | disclosed |
| US-20230218578-A1 | BENZOPYRAZOLE COMPOUNDS AND ANALOGUES THEREOF | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2023-07-13 | — | — | US | disclosed |
| US-20230218578-A1 | BENZOPYRAZOLE COMPOUNDS AND ANALOGUES THEREOF | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2023-07-13 | — | — | US | disclosed |
| US-11559515-B2 | Indole compounds and analogues thereof | BIOCRYST PHARMACEUTICALS, INC. (US) | 2023-01-24 | — | — | US | disclosed |
| CN-115490751-A | Factor D inhibitors | 拜奥克里斯特制药公司 | 2022-12-20 | — | — | CN | disclosed |
| CN-109121414-B | Benzopyrazole compounds and analogs thereof | 拜奥克里斯特制药公司 | 2022-07-05 | — | — | CN | disclosed |
| EP-3411411-B3 | 1H-INDAZOLE-3-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS FACTOR D INHIBITORS FOR TREATING DISEASES CHARACTERIZED BY ABERRANT COMPLEMENT SYSTEM ACTIVITY, SUCH AS E.G. IMMUNOLOGICAL DISORDERS | BIOCRYST PHARM INC (US) | 2022-01-26 | — | — | EP | disclosed |
| EP-3411411-B3 | 1H-INDAZOLE-3-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS FACTOR D INHIBITORS FOR TREATING DISEASES CHARACTERIZED BY ABERRANT COMPLEMENT SYSTEM ACTIVITY, SUCH AS E.G. IMMUNOLOGICAL DISORDERS | BIOCRYST PHARM INC (US) | 2022-01-26 | — | — | EP | disclosed |
| EP-3925956-A1 | 1H-INDAZOLE-3-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS FACTOR D INHIBITORS FOR TREATING DISEASES CHARACTERIZED BY ABERRANT COMPLEMENT SYSTEM ACTIVITY, SUCH AS E.G. IMMUNOLOGICAL DISORDERS | BioCryst Pharmaceuticals, Inc. (US) | 2021-12-22 | — | — | EP | disclosed |
| EP-3925956-A1 | 1H-INDAZOLE-3-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS FACTOR D INHIBITORS FOR TREATING DISEASES CHARACTERIZED BY ABERRANT COMPLEMENT SYSTEM ACTIVITY, SUCH AS E.G. IMMUNOLOGICAL DISORDERS | BioCryst Pharmaceuticals, Inc. (US) | 2021-12-22 | — | — | EP | disclosed |
| EP-3411411-B1 | 1H-INDAZOLE-3-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS FACTOR D INHIBITORS FOR TREATING DISEASES CHARACTERIZED BY ABERRANT COMPLEMENT SYSTEM ACTIVITY, SUCH AS E.G. IMMUNOLOGICAL DISORDERS | BIOCRYST PHARM INC (US) | 2021-05-19 | — | — | EP | disclosed |
| EP-3411411-B1 | 1H-INDAZOLE-3-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS FACTOR D INHIBITORS FOR TREATING DISEASES CHARACTERIZED BY ABERRANT COMPLEMENT SYSTEM ACTIVITY, SUCH AS E.G. IMMUNOLOGICAL DISORDERS | BIOCRYST PHARM INC (US) | 2021-05-19 | — | — | EP | disclosed |
| US-10849883-B2 | Benzopyrazole compounds and analogues thereof | BIOCRYST PHARMACEUTICALS, INC. (US) | 2020-12-01 | — | — | US | disclosed |
| US-20190142802-A1 | BENZOPYRAZOLE COMPOUNDS AND ANALOGUES THEREOF | BIOCRYST PHARMACEUTICALS, INC. (US) | 2019-05-16 | — | — | US | disclosed |
| EP-3411411-A1 | BENZOPYRAZOLE COMPOUNDS AND ANALOGUES THEREOF | Biocryst Pharmaceuticals, Inc. (US) | 2018-12-12 | — | — | EP | disclosed |
| WO-2017136395-A1 | BENZOPYRAZOLE COMPOUNDS AND ANALOGUES THEREOF | BIOCRYST PHARMACEUTICALS, INC. (US) | 2017-08-10 | — | — | WO | disclosed |
| WO-2017136395-A1 | BENZOPYRAZOLE COMPOUNDS AND ANALOGUES THEREOF | BIOCRYST PHARMACEUTICALS, INC. (US) | 2017-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12485109-B2 | Pyrrolo 12.3-dipyrimidine compounds and analogues thereof | C5, DPYD, C9 | JAK2 1382/4885PDPK1 676/4885IDO1 885/4885 |
| US-20230218578-A1 | BENZOPYRAZOLE COMPOUNDS AND ANALOGUES THEREOF | C9, C5, C1QBP | JAK2 1396/4885PDPK1 1003/4885IDO1 2209/4885 |
| US-11559515-B2 | Indole compounds and analogues thereof | C5, IDO1, IDO2 | JAK2 713/4885PDPK1 1416/4885IDO1 2/4885 |
| US-10849883-B2 | Benzopyrazole compounds and analogues thereof | C9, C5, C1QBP | JAK2 1396/4885PDPK1 1003/4885IDO1 2209/4885 |
| US-20190142802-A1 | BENZOPYRAZOLE COMPOUNDS AND ANALOGUES THEREOF | C9, C5, C1QBP | JAK2 1396/4885PDPK1 1003/4885IDO1 2209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.